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The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients. Methods. All
consecutive patients over 74 years treated with oxaliplatin or irinotecan for metastatic colorectal cancer were enrolled. The tumour
response was assessed every 2–3 months and toxicity was collected at each cycle according to World Health Organisation criteria. A
total of 66 patients were enrolled from 12 centres. The median age was 78 years (range, 75–88 years); 39 patients had no severe
comorbidity according to the Charlson score. In total, 44 and 22 patients received oxaliplatin or irinotecan, respectively, in
combination with 5-fluororuracil7folinic acid or raltitrexed in 64 patients. A total of 545 chemotherapy cycles were administered in
first (41%), second (51%) or third line (8%). A dose reduction occurred in 190 cycles (35%). Complete response, partial response and
stabilisation occurred in 1.5, 20 and 47% of patients, respectively. The median time to progression and overall survival were 6.8 and
11.2 months in first line and 6.3 and 11.6 months in second line, respectively. Grade 3 and 4 toxicity occurred in 42% of patients:
neutropenia 17%, diarrhoea 15%, neuropathy 11%, nausea and vomiting 8% and thrombopenia 6%. There was no treatment-related
death. In selected elderly patients, chemotherapy with oxaliplatin or irinotecan is feasible with manageable toxicity.
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Colorectal cancer is the second most frequent cancer in Europe
(Bray et al, 2002) and 40% of patients are of age 74 years and more
at diagnosis (Gatta et al, 1998). Nevertheless, patients over 75 years
have been usually excluded from randomised clinical trials
evaluating chemotherapy for advanced colorectal cancer (Trimble
et al, 1994; Kohne et al, 2001). Few data are available on
chemotherapy in elderly patients, but it has been suggested that
5-fluorouracil (5-FU)-based chemotherapy efficacy was compar-
able to that in younger patients (Stein et al, 1995; Chiara et al,
1998; Mabro et al., 1999; Popescu et al., 1999; Magne et al., 2002).
Tolerance was comparable except in one study evaluating
chemotherapy with bolus 5-FU (Stein et al, 1995). A survival
benefit was demonstrated in one unpublished randomised study
comparing 5-FU-based chemotherapy to best supportive care in
elderly patients (Beretta et al, 1997). In the adjuvant setting, a
pooled analysis of randomised trials with 5-FU-based chemother-
apy confirmed the improvement of disease-free survival and
overall survival (OS) with chemotherapy, even in patients over 70
years (Sargent et al, 2001).
Oxaliplatin (de Gramont et al, 2000) and irinotecan (Douillard
et al, 2000), in combination with 5-FU–leucovorin, have demon-
strated their efficacy in advanced colorectal cancer with a better
tumour response rate than 5-FU and leucovorin alone. After 5-FU
failure, irinotecan as second-line chemotherapy has demonstrated
a survival advantage compared to best supportive care in advanced
colorectal cancer (Cunningham et al, 1998). Combination therapy,
however, has an increased toxicity compared to 5-FU alone,
especially neutropenia, diarrhoea and neurologic toxicity with
oxaliplatin and neutropenia, and diarrhoea with irinotecan.
No data from clinical trials are available about chemotherapy
with oxaliplatin or irinotecan in patients aged 75 years and more
with advanced colorectal cancer. We report the result of tolerance
and efficacy of oxaliplatin- or irinotecan-based chemotherapy in a
multicentre observational cohort of patients of age 75 years and
more with an advanced colorectal cancer.
PATIENTS AND METHODS
Patients
Data were collected from 12 centres. Each investigator included all
consecutives patients over 74 years treated with oxaliplatin or
irinotecan for advanced colorectal carcinoma from January 1999 to
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lJune 2002. All patients had a histologically proven colorectal
adenocarcinoma. All the regimens containing oxaliplatin or
irinotecan were considered either in association with 5-FU/
leucovorin, oral 5-FU or raltitrexed. Only the first regimen was
considered for evaluation in patients receiving both oxaliplatin
and irinotecan sequentially. Patients were divided into two groups:
group 1 patients 75–79 years old and group 2 patients 80 years old
and over. The following clinical and biological variables were
recorded: age, sex, body mass index, primary localisation, sites of
metastasis, World Health Organisation (WHO) performance status
(PS), Charlson comorbidity score (Charlson et al, 1987), haemo-
globin, creatinin clearance (according to Cockroft method),
alkaline phosphatase and carcinoembryonic antigen.
Chemotherapy
The chemotherapy regimens used were: FOLFOX 4 (leucovorin
200mgm
 2day
 1 as a 2-h infusion followed by bolus 5-FU
400mgm
 2day
 1 and a 22-h 5-FU infusion of 600mgm
 2day
 1,
repeated for 2 consecutive days every 2 weeks. Oxaliplatin
85mgm
 2 was given on day 1 as a 2-h infusion concurrent with
leucovorin) (de Gramont et al, 2000), FOLFOX 6 (oxaliplatin
100mgm
 2 was infused with leucovorin 400mgm
 2 as a 2-h
infusion on day 1, followed by bolus 400mgm
 2 and a 46-h
infusion 2400mgm
 2 of 5-FU, every 2 weeks) (Maindrault-Goebel
et al, 2000), FOLFOX 7 consisted of the same regimen with
oxaliplatin 130mgm
 2 (Maindrault-Goebel et al, 2001), ELOXFU-
3 (leucovorin 200mgm
 2 as a 2-h infusion followed by bolus 5FU
400mgm
 2 and a 48-h infusion of 2400mgm
 2 and oxaliplatin
130mgm
 2 on day 1 every 3 weeks) (Ducreux et al, 1999),
LV5FU2-irinotecan (leucovorin 200mgm
 2day
 1 as a 2-h infu-
sion followed by bolus 5-FU 400mgm
 2day
 1 and a 22-h 5-FU
infusion of 600mgm
 2day
 1, repeated for 2 consecutive days
every 2 weeks. Irinotecan 180mgm
 2 was given on day 1 as a 1.5-h
infusion concurrent with leucovorin) (Douillard et al, 2000).
According to evidence-based medicine, treatment was continued
until disease progression or unacceptable toxicity occurred or until
a patient chose to discontinue it.
Study parameters
When measurable, tumour response was assessed with computed
tomography (CT) examination every 2–3 months according to
WHO criteria. A complete response was defined as the complete
disappearance of all clinically assessable disease, and a partial
response was defined as a decrease of at least 50% of the sum of the
products of the diameters of measurable lesions. Stable disease was
defined as a decrease of less than 50% or an increase of less than
25% of measurable lesions, and progressive disease was defined as
an increase of at least 25% of measurable lesions or the appearance
of new malignant lesion(s). Progression-free survival (PFS) was
defined as the time interval from the beginning of oxaliplatin- or
irinotecan-based chemotherapy to the date of disease progression
or, if the patient died without evidence of progression, to the date
of death. OS lasted from the date of the beginning of oxaliplatin- or
irinotecan-based chemotherapy to the date of death or the date
when the patient was seen for the last time. Toxicities were
collected at each cure according to WHO criteria.
Statistical analysis
Since this was not a randomised study, only patient characteristics
at inclusion were statistically compared, using w
2 test for
categorical variables and Student’s t-test for continuous variables.
OS and PFS were calculated using the Kaplan–Meier method. For
all statistical tests, P-values less than or equal to 0.05 were
considered significant.
RESULTS
Patients and treatment
Data from 66 consecutive patients treated from January 1999 to June
2002 were collected. Patient characteristics are presented in Table 1.
The median age was 78 years (range, 75–88 years). In all, 48
patients were 75–79 years old (group 1) and 18 were aged 80 or over
(group 2). For groups 1 and 2, the median ages were, respectively, 77
years (range, 74–79 years) and 81 years (range, 80–88 years). Of the
66 patients, 39 had no severe comorbidity according to the Charlson
index. No significant difference for sex, site of primary tumour,
number of metastasic sites and comorbidity were observed between
patients of groups 1 and 2. Group 2 patients had a significantly
poorer PS. Creatinin clearance was significantly lower in group 2
than in group 1 (Table 1). There was no significant difference in
baseline characteristics between patients treated in first line and
patients treated in second line (Table 1).
Out of the 66 patients, 44 received an oxaliplatin-based regimen
and 22 received an irinotecan-based regimen. A total of 60 patients
were treated with a combination of oxaliplatin or irinotecan with
5-FU/leucovorin (Table 2). Patients received oxaliplatin- or
irinotecan-based regimen mainly as second-line treatment (51%)
after failure of 5-FU (Table 3).
Among the 545 cycles of chemotherapy administered, 190 cycles
(35%) were carried out with a dose reduction of 126 (31%) in
group 1 and 64 (48%) in group 2.
Toxicity
In all, 28 (42%) patients experienced grade 3 and 4 toxicity
(Table 4). The main severe toxicities were neutropenia in 11
patients and diarrhoea in 10 patients. The toxicity pattern was
similar in groups 1 and 2. Definitive treatment interruption for
toxicity occurred in four of the nine (44%) patients with a
Charlson score higher than 2 and in seven of the 57 (12%) patients
with a Charlson score equal or less than 2.
Objective tumoral responses
Three patients (4.5%) were not evaluable for tumoral response.
Objective responses were observed in 14 patients (21%) (Table 5).
Tumour control defined as an objective response or stabilisation
was obtained in 44 patients (67%).
PFS and OS
For all patients, the median PFS was 6.3 (range, 1–30.9) months
(Figure 1). PFS was 4.5 (range, 1.4–13.2) months for group 2
patients and 7.3 (range, 1–30.9) months for group 1 patients
(Figure 2). The median OS was 11.8 (range, 1.8–32.8) months
(Figure 3). The median OS was 9.9 (range, 2.3–13.9) months for
group 2 patients and 12.1 (range, 1.8–32.8) months for group 1
patients (Figure 4). The median OS from the beginning of the first-
line chemotherapy was 16.7 (range, 4–42.3) months. The survival
rate from the beginning of the first-line chemotherapy was 72% at
1 year and 34% at 2 years.
For the 27 patients treated in first line, the median PFS was 6.8
months (range, 1–29.2) and the median OS was 11.2 months
(range, 4–29.2). For the 34 patients treated in second line, the
median PFS was 6.3 months (range, 1–30.9) and the median OS
was 11.6 months (range, 1.8–32.8). The median OS from the
beginning of the first-line chemotherapy was 20.6 months (range,
5.8–42.3) in these 34 patients.
PS and weight improvement
Among the 53 patients with an initial PS 41, six were not
evaluable for PS evolution and 15 (32%) had a PS improvement. A
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ltotal of 28% of all the patients had a gain in weight during the
treatment.
DISCUSSION
This is the first study of tolerance and efficacy of oxaliplatin- and
irinotecan-based chemotherapy in elderly patients. Our results
show that oxaliplatin- or irinotecan-based chemotherapy in elderly
patients is feasible and safe.
A total of 42% of the patients experienced severe toxicity
without treatment-related death. Previous retrospective studies
evaluating 5-FUþleucovorin regimens in an elderly population
reported severe toxicity in 20% of patients treated with the
LV5FU2 regimen (Mabro et al, 1999) and in 58% of patients
Table 1 Patient characteristics
Patients characteristics All patients, n¼66 (%) Group 1, n¼48 (%) Group 2, n¼18 (%) First line, n¼27 (%) Second line, n¼34 (%)
Sex
Male 39 (59) 25 (52) 14 (78)* 15 (56) 20 (59)
Female 27 (41) 23 (48) 4 (22) 12 (44) 14 (41)
Site of primary tumour
Colon 52 (79) 38 (79) 14 (78) 20 (74) 27 (79)
Rectum 14 (21) 10 (21) 4 (22) 7 (26) 7 (21)
No. of metastatic site(s)
1 38 (58) 30 (62) 8 (44) 16 (59) 19 (56)
2 19 (29) 11 (23) 8 (44) 8 (30) 10 (29)
42 9 (14) 7 (15) 2 (12) 3 (11) 5 (15)
Charlson comorbidity index
0 39 (59) 29 (60) 10 (55) 16 (59) 21 (62)
1–2 18 (27) 13 (27) 5 (28) 6 (22) 10 (29)
42 9 (14) 6 (13) 3 (17) 5 (19) 3 (9)
Performance status
0 13 (20) 11 (23) 2 (11) 3 (11) 8 (24)
1 31 (47) 22 (46) 9 (50) 14 (52) 14 (41)
2 19 (29) 15 (31) 4 (22) 8 (30) 11 (32)
3 3 (4) 0 (0) 3 (17)** 2 (7) 1 (3)
Mean creatinin clearance (mlmin
 1) 58.971.8 61.472.1 5273.5*** 6272.5 5772.6
Mean haemoglobin (gdl
 1)1 2 70.2 11.870.2 12.570.3 11.870.2 12.170.3
CEA o5 (ngml
 1) 11 (17) 9 (19) 2 (11) 5 (18) 6 (18)
45–50ngml
 1 19 (29) 13 (27) 6 (33) 7 (26) 9 (26)
450ngml
 1 31 (47) 22 (46) 9 (50) 15 (56) 15 (44)
Not done 5 (7) 4 (8) 1 (6) 0 4 (12)
Alkaline phosphatase
oN 42 (64) 34 (71) 8 (45) 19 (70) 20 (59)
4N–2N 11 (17) 5 (10) 6 (33) 4 (15) 5 (15)
42N 10 (15) 6 (13) 4 (22) 4 (15) 6 (17)
Not done 3 (4) 3 (6) 0**** 0 3 (9)
*P¼0.058. **P¼0.025. ***P¼0.04. ****P¼0.044.
Table 2 Chemotherapy characteristics
Chemotherapy regimens
All patients,
n¼66 (%)
Mean number
of cycles
a
Group 1,
n¼48 (%)
Mean number
of cycle
Group 2,
n¼18 (%)
Mean number
of cycle
LV5FU2-irinotecan 21 (32) 10.971.3 15 (31) 10.771.4 6 (33) 11.573.2
FOLFOX 4 20 (30) 8.270.7 17 (36) 8.870.8 3 (17) 5.371.4
FOLFOX 6 12 (18) 7.871 8 (17) 871.4 4 (22) 7.571.8
ELOXFU 3 5 (8) 3.470.8 4 (8) 3.571 1 (6) 3.0
FOLFOX 7 2 (3) 7.071 2 (4) 7.071— —
Oxaliplatin monotherapy 2 (3) 5.072 2 (4) 5.072— —
Others
b 4 (6) 4.071 — — 4 (22) 4.071
Overall 10.870.8 10.270.8 12.572.2
aLV5FU2-irinotecan, FOLFOX 4, FOLFOX 6 and FOLFOX 7 are biweekly regimens; ELOXFU 3, oxaliplatin monotherapy and other regimens are three-weekly regimens.
bOne
patient was treated with an association of raltitrexed and oxaliplatin, two patients with an association of capecitabine and oxaliplatin and one patient with an association of
raltitrexed and irinotecan.
Table 3 Repartition of oxaliplatin or irinotecan chemotherapy line
Chemotherapy
line
All patients,
n¼66 (%)
Group 1,
n¼48 (%)
Group 2,
n¼18 (%)
First line 27 (41) 20 (42) 7 (39)
Oxaliplatin 19 14 5
Irinotecan 8 6 2
Second line 34 (51) 26 (54) 8 (44)
Oxaliplatin 21 17 4
Irinotecan 13 9 4
Third line 5 (8) 2 (4) 3 (17)
Oxaliplatin 4 2 2
Irinotecan 1 — 1
Oxaliplatin or irinotecan chemotherapy in the elderly
T Aparicio et al
1441
British Journal of Cancer (2003) 89(8), 1439–1444 & 2003 Cancer Research UK
C
l
i
n
i
c
a
ltreated with the 5-FU bolus regimen (Stein et al, 1995). We report
severe neutropenia in 14 and 23% of patients treated with
oxaliplatin and irinotecan, respectively. Previous studies in
nonelderly patients reported severe neutropenia in 36–41%
(Andre et al, 1999; de Gramont et al, 2000) with oxaliplatin and
29–54% (Douillard et al, 2000; Saltz et al, 2000) with irinotecan.
In our study, severe neuropathy occurred in 16% of patients
treated with oxaliplatin; previous studies reported severed neuro-
pathy in 18 and 20% (Andre et al, 1999; de Gramont et al,
2000). Severe diarrhoea occurred in 27% of patients treated
with irinotecan. Previous studies reported severe diarrhoea in
22–44% (Douillard et al, 2000; Saltz et al, 2000). A full dose
of chemotherapy was administered in 65% of the cycles.
Previous studies in nonelderly patients reported a dose intensity
of 73% for oxaliplatin (de Gramont et al, 2000) and 72–93% for
irinotecan (Douillard et al, 2000; Saltz et al, 2000) in first-line
chemotherapy. The frequent dose reduction observed in our
report, especially in group 2, could partly explain the mild
toxicity.
The overall objective response rate was 22%; 38% in first-line
treatment. The response rates reported in previous studies in
Table 4 Maximum toxicity per patient
Grade 3 and 4 toxicity
a
All patients,
n¼66 (%)
Oxaliplatin-
based regimen,
n¼44 (%)
Irinotecan-
based regimen,
n¼22 (%)
Group 1,
n¼48 (%)
Group 2,
n¼18 (%)
Any grades 3 and 4 (except alopecia) 28 (42) 16 (36) 12 (54) 20 (42) 8 (44)
Neutropenia 11 (17) 6 (14) 5 (23) 8 (17) 3 (17)
Thrombopenia 4 (6) 4 (9) 0 2 (4) 2 (11)
Anaemia 1 (1.5) 1 (2) 0 1 (2) 0
Nausea and vomiting 5 (8) 3 (7) 2 (9) 4 (8) 1 (6)
Diarrhoea 10 (15) 4 (9) 6 (27) 7 (15) 2 (11)
Stomatitis 2 (3) 2 (5) 0 2 (4) 0
Neurologic 7 (11) 7 (16) 0 5 (10) 2 (11)
Treatment interruption for toxicity 11 (17) 8 (18) 3 (14) 9 (19) 2 (11)
Number of delayed cycles for toxicity/
total number of cycles
38/545 (7) 24/309 (8) 14/236 (6) 27/411 (7) 11/134 (8)
aAccording to WHO grade.
Table 5 Tumoral responses
All
patients,
n¼66 (%)
First line,
n¼27 (%)
Second
line,
n¼34 (%)
Group 1,
n¼48 (%)
Group 2,
n¼18 (%)
Complete
response
1 (1.5) 1 (4) 0 0 1 (6)
Partial
response
13 (20) 9 (33) 4 (12) 11 (23) 2 (11)
Stable
disease
31 (47) 12 (44) 17 (50) 20 (42) 11 (61)
Progression 18 (27) 4 (15) 12 (35) 14 (29) 4 (22)
Not
evaluable
3 (4.5) 1 (4) 1 (3) 3 (6) 0
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Figure 1 PFS curve.
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Figure 2 PFS curves according to age group.
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Figure 3 OS curve.
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lelderly patients treated with a 5-FU- or raltitrexed-based regimen
were 18% (Chiara et al, 1998), 22% (Feliu et al, 2002), 24%
(Popescu et al, 1999), 26% (Magne et al, 2002) and 44% (Mabro
et al, 1999). The response rate in nonelderly patients treated in first
line with an oxaliplatin- or irinotecan-based regimen is about 50%
(de Gramont et al, 2000; Douillard et al, 2000; Saltz et al, 2000). In
second line, the response rates ranged from 17% (Rougier et al,
1997) to 46% (de Gramont et al, 1997). The response rates
observed in our study in first-line treatment seem to be higher
than those generally obtained with 5-FU alone in elderly patients
and comparable to those obtained with oxaliplatin or irinotecan in
nonelderly patients. In second line, the response rates seem to be
lower than those published with oxaliplatin or irinotecan in
nonelderly patients.
We observed a median OS of 11.2 months in first line. It was 9.6
(Feliu et al, 2002), 9.7 (Popescu et al, 1999), 16.4 (Mabro et al,
1999) and 14 months (Magne et al, 2002) in previous studies where
elderly patients were treated with a 5-FU- or raltitrexed-based
regimen. Nevertheless, although we did not observe a better OS
with oxaliplatin or irinotecan than in previous studies with 5-FU or
raltitrexed, it must be pointed out that in all these studies the
median age was younger and only few patients over 79 years were
considered. We have suggested that age over 79 years is associated
with poor survival. This population represents 27% of the patients
in our study and could explain the poor OS observed. Nevertheless,
the survival observed in our elderly patients is poorer than the one
reported in prospective studies in younger patients in first-line
treatment (de Gramont et al, 2000; Douillard et al, 2000; Saltz et al,
2000). In patients treated in second line with oxaliplatin or
irinotecan, we observed an 11.6 month median survival from the
beginning of second line and a 20.6 month median survival from
the beginning of first line. These data prompted us to use a second-
line chemotherapy in the elderly after first-line failure. Never-
theless, the discrepancy between OS of patients treated in first line
with oxaliplatin or irinotecan and OS from the beginning of
chemotherapy in patients treated in second line with oxaliplatin or
irinotecan suggest that tumours of patients treated in second line
had a slower growth rate.
The median PFS in first line was 6.8 months, which is
comparable with PFS reported in younger patients: 9 months with
oxaliplatin (de Gramont et al, 2000) and 6.7–7 months with
irinotecan (Douillard et al, 2000; Saltz et al, 2000). An improve-
ment of PS was noted in 32% of the patients with initial degraded
PS; this is comparable with the 42% of improvement of PS reported
with oxaliplatin in younger patients (de Gramont et al, 2000). In
elderly patients treated with 5-FU alone, PS improvement varied
from 26 to 56% (Mabro et al, 1999; Magne et al, 2002).
Nevertheless, it is necessary to evaluate the influence of
chemotherapy on quality of life and patient autonomy in a
prospective study on elderly patients. In our study, the majority of
the patients had no or little severe comorbidity. This suggests that
the population is selected. This is the first study using the Charlson
comorbidity score for elderly patients treated for metastatic
colorectal carcinoma. A prognostic value of Charlson 42 was
suggested for the occurrence of definitive treatment interruption
for toxicity. A stratification according to the Charlson comorbidity
score should be considered in prospective studies in elderly
patients.
We conclude that chemotherapy with oxaliplatin or irinotecan
in selected elderly patients is feasible with manageable toxicity.
Improvements of PS and prolonged PFS and OS were obtained, but
the benefit is weaker after 79 years. Moreover, second-line
chemotherapy should be considered whenever it is possible in
elderly patients. Prospective studies are needed to establish the
benefit of the different chemotherapy regimens for quality of life
and autonomy in elderly patients.
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